Radioembolization (Y90) achieves higher response rates and reduces progression risk compared with DEB-TACE in hepatocellular carcinoma

Hepatology Communications 2026 Open access

Read full text
Authors: Kelley Núñez, Navid Hasani, Julie Cronan, Juan Gimenez, Ari Cohen, Tyler Allan Sandow, Paul Thevenot
DOI: 10.1097/hc9.0000000000000935
Cited by: 1
References: 33

Abstract

BACKGROUND: Drug-eluting bead transarterial chemoembolization (DEB-TACE) and yttrium-90 (90Y) radioembolization are approved therapies to treat hepatocellular carcinoma (HCC). Several randomized controlled trials and propensity score-matched studies (PSM) have been conducted to compare these 2 treatments; many utilized 90Y standard dosimetry (

Fields of Study & Subjects

Hepatocellular Carcinoma Treatment and Prognosis Cholangiocarcinoma and Gallbladder Cancer Studies Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
Hepatology Communications
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
10
Issue
5
Publication date
17 April 2026
Language
EN